chevron_leftBack
As of 17 June 2026, BioInfra Co., Ltd. has a market cap of $13.62M USD, ranking #39646 globally and #2502 in South Korea.
It ranks #9096 in the Industrials sector, and #1150 in the Specialty Business Services industry.
Key Stats
Market Cap
$13.62MUSD
20.55B KRW
Enterprise Value
$16.06MUSD
24.24B KRW
Revenue (TTM)
$15.34MUSD
23.15B KRW
EBITDA (TTM)
-$1.88MUSD
-2.84B KRW
Net Income (TTM)
-$6.05MUSD
-9.13B KRW
EBITDA Margin
-12%
Profit Margin
-39%
PS Ratio
0.9
PB Ratio
1.2
Company Profile
Country (HQ)
Sector
Industrials
Industry
Specialty Business Services
CEO
Sangdeuk Lee
open_in_new
Founded
2007
Website
bioinfrakorea.co.kr
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| 1.4% | -0.8% | 6% | -13% | -14% | -33% |
News
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
199730
주식회사 바이오인프라
ISIN: KR7199730003
Shares Out.:
Shares Outstanding:
4.864M1
Shares Float:
4.834M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
4,225 KRW |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About BioInfra Co., Ltd.
BioInfra Co., Ltd. operates as a contract research organization for phase 1 clinical trials. The company provides clinical, which undertakes clinical trials for new drug development approval (Phase I-III) and late clinical trials; immunoassay, which performs pharmacokinetic, toxicokinetic, and biomarker analysis of polymer biopharmaceuticals; and testing and inspection, which provides finished drug product quality inspection, comparative dissolution testing, and long-term stability testing. It also specializes in bioequivalence testing of generic drugs, phase 1 clinical trials for new and improved drugs; and sample analysis services for new drug substances. The company was founded in 2007 and is based in Yongin-si, South Korea.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
KRX: 352820
|
$7.19B
53K%
10.85T KRW
|
-
|
|
KRX: 377300
|
$5.07B
37K%
7.65T KRW
|
169.0
|
|
KRX: 0009K0
|
$2.09B
15K%
3.15T KRW
|
627.7
|
|
KRX: 012750
|
$1.94B
14K%
2.93T KRW
|
16.4
|
|
KRX: 131970
|
$1.68B
12K%
2.54T KRW
|
69.0
|
|
KRX: 174900
|
$665.33M
5K%
1.0T KRW
|
-
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NASDAQ: SHOP
|
$158.14B
1M%
|
129.8
|
|
STO: VSURE
|
$133.29B
979K%
114.8B EUR
|
-
|
|
NASDAQ: CTAS
|
$69.6B
511K%
|
36.8
|
|
LSE: REL
|
$63.92B
469K%
47.6B GBP
|
23.9
|
|
NASDAQ: PYPL
|
$45.83B
336K%
|
9.4
|
|
|
T
NEO: TRI
|
$41.8B
307K%
56.91B CAD
|
-
|
chevron_leftBack